Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Abstract Background Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood. Methods Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regimens in a single institution from September 2017 to...

Full description

Bibliographic Details
Main Authors: Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji, Kohei Shitara
Format: Article
Language:English
Published: BMJ Publishing Group 2019-01-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Nivolumab
PD-1 inhibitor
Predictive factor
Gastric cancer
Responders
Online Access:http://link.springer.com/article/10.1186/s40425-019-0514-3

Internet

http://link.springer.com/article/10.1186/s40425-019-0514-3

Similar Items